Factors affecting the duration of phase 1 of dexamethasone-immunosuppressant pulse therapy for pemphigus group of disorders: A 10-year retrospective study in a tertiary care center
Context: Dexamethasone-immunosuppressant pulse therapy introduced by Pasricha et al. in 1981 as a treatment for long-term remission in pemphigus group of disorders has gained wide acceptance in many places, especially India. Since the overall duration of treatment is determined by the duration of ph...
Main Authors: | Vidya Mundakkat, Rajiv Sridharan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Indian Dermatology Online Journal |
Subjects: | |
Online Access: | http://www.idoj.in/article.asp?issn=2229-5178;year=2018;volume=9;issue=6;spage=405;epage=408;aulast=Mundakkat |
Similar Items
-
Dexamethasone cyclophosphamid pulse therapy in pemphigus-appraisal of its outcome
by: Prabhash Kulhari, et al.
Published: (2012-01-01) -
Comparative retrospective evaluation of efficacy of rituximab therapy with dexamethasone cyclophosphamide pulse therapy in patients of pemphigus vulgaris at a tertiary care hospital
by: Preema Sinha, et al.
Published: (2020-01-01) -
Determination Of Interleukine-10 In Cancer Patients In Stages Iii And Iv Treated With Dexamethasone.
by: Heber Siachoque, et al.
Published: (2005-12-01) -
Probiotic fermentation of Ganoderma lucidum fruiting body extracts promoted its immunostimulatory activity in mice with dexamethasone-induced immunosuppression
by: Yuyuan Li, et al.
Published: (2021-09-01) -
Adverse effects of parenteral dexamethasone in the treatment of pemphigus vulgaris
by: Mohammad Jamal Uddin, et al.
Published: (2016-08-01)